Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Aktis Oncology, Inc.NASDAQ: AKTS
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables of $2.2M in Q1 FY2026
Q1 FY2026 net receivables was $2.2M.
Context
- Net receivables amounted to 0.4% of total assets at the end of Q1 FY2026.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 net receivables of $2.2M is the 4th highest of the 6 companies compared; the peer median is $10.43M.
- Net receivables amounts to 0.4% of total assets for AKTS, versus a peer median of 4.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $81.07M | +28.5% | +9.0% | 7.6% | |
| Mar 2026 | $40.92M | -11.8% | +18.8% | 6.3% | |
| Mar 2026 | $10.43M | -1.1% | -38.0% | 4.8% | |
| Mar 2026 | $2.2M | — | — | 0.4% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AKTS) | $10.43M | -1.1% | +9.0% | 4.8% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.